The discovery of aberrantly methylated signaling pathways including the circadian rhythm, CREB, GI, G-Protein coupled receptor, cAMP-mediated, endocannabinoid cancer inhibition, white adipose tissue browning, dopamine receptor, ephrin receptor, glutamate receptor and axonal guidance signaling pathways implicated in CRC suggests that DNA methylation has promise for the discovery of potential therapeutic targets. This evidence concerns the gene CREB1 and colorectal carcinoma.